Active ingredients: mepolizumab
What it is used for
Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical 2 Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear to opalescent, colourless to pale yellow to pale brown solution in a pre-filled syringe.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient mepolizumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems